CN112367995A - 艾伏尼布形式和药物组合物 - Google Patents

艾伏尼布形式和药物组合物 Download PDF

Info

Publication number
CN112367995A
CN112367995A CN201980045552.5A CN201980045552A CN112367995A CN 112367995 A CN112367995 A CN 112367995A CN 201980045552 A CN201980045552 A CN 201980045552A CN 112367995 A CN112367995 A CN 112367995A
Authority
CN
China
Prior art keywords
amino
difluorocyclobutyl
chlorophenyl
oxoethyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980045552.5A
Other languages
English (en)
Chinese (zh)
Inventor
C-H.顾
J.P.西泽莫尔
S.张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CN112367995A publication Critical patent/CN112367995A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980045552.5A 2018-07-06 2019-07-02 艾伏尼布形式和药物组合物 Pending CN112367995A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862694596P 2018-07-06 2018-07-06
US62/694,596 2018-07-06
PCT/US2019/040257 WO2020010058A1 (en) 2018-07-06 2019-07-02 Ivosidenib forms and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CN112367995A true CN112367995A (zh) 2021-02-12

Family

ID=69059942

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980045552.5A Pending CN112367995A (zh) 2018-07-06 2019-07-02 艾伏尼布形式和药物组合物

Country Status (18)

Country Link
US (1) US12264148B2 (enExample)
EP (2) EP4603147A3 (enExample)
JP (2) JP7621242B2 (enExample)
KR (2) KR20250164882A (enExample)
CN (1) CN112367995A (enExample)
AU (2) AU2019299352B2 (enExample)
BR (1) BR112021000156A2 (enExample)
CA (1) CA3103498A1 (enExample)
EA (1) EA202190217A1 (enExample)
IL (3) IL327008A (enExample)
MA (1) MA53099A (enExample)
MX (2) MX2021000068A (enExample)
PH (1) PH12021550017A1 (enExample)
SG (1) SG11202012763TA (enExample)
TW (2) TWI911130B (enExample)
UA (1) UA129800C2 (enExample)
WO (1) WO2020010058A1 (enExample)
ZA (1) ZA202008034B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4010331T (pt) * 2019-08-08 2024-01-08 Servier Lab Um método de preparação do ivosidenib e de um seu intermediário
GB201912411D0 (en) * 2019-08-29 2019-10-16 Johnson Matthey Plc Crystalline forms of ivosidenib
AR133410A1 (es) 2023-08-01 2025-09-24 Servier Lab Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103459394A (zh) * 2011-04-08 2013-12-18 辉瑞大药厂 结晶和非结晶形式的托法替尼，以及包含托法替尼和渗透增强剂的药物组合物
CN104902878A (zh) * 2012-09-06 2015-09-09 拜尔健康护理有限责任公司 含有瑞戈非尼的包衣的药物组合物
CN106255498A (zh) * 2014-03-14 2016-12-21 阿吉奥斯制药公司 治疗活性化合物的药物组合物
US20170007661A1 (en) * 2014-03-14 2017-01-12 Agios Pharmaceuticals, Inc Pharmaceutical compositions of therapeutically active compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MD3362066T2 (ro) * 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
EP3717470A1 (en) * 2017-11-27 2020-10-07 Assia Chemical Industries Ltd Solid state forms of ivosidenib

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103459394A (zh) * 2011-04-08 2013-12-18 辉瑞大药厂 结晶和非结晶形式的托法替尼，以及包含托法替尼和渗透增强剂的药物组合物
CN104902878A (zh) * 2012-09-06 2015-09-09 拜尔健康护理有限责任公司 含有瑞戈非尼的包衣的药物组合物
CN106255498A (zh) * 2014-03-14 2016-12-21 阿吉奥斯制药公司 治疗活性化合物的药物组合物
US20170007661A1 (en) * 2014-03-14 2017-01-12 Agios Pharmaceuticals, Inc Pharmaceutical compositions of therapeutically active compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MINO R. CAIRA: "Crystalline Polymorphism of Organic Compounds", 《TOPICS IN CURRENT CHEMISTRY》, vol. 198, pages 163 - 208, XP008166276, DOI: 10.1007/3-540-69178-2_5 *

Also Published As

Publication number Publication date
MX2021000068A (es) 2021-03-25
TWI911130B (zh) 2026-01-01
TW202019419A (zh) 2020-06-01
IL315423B2 (en) 2026-08-01
TW202543623A (zh) 2025-11-16
JP2021529805A (ja) 2021-11-04
KR102919157B1 (ko) 2026-01-27
EA202190217A1 (ru) 2021-04-16
EP3817744A4 (en) 2022-07-13
IL315423B1 (en) 2026-04-01
CA3103498A1 (en) 2020-01-09
JP7621242B2 (ja) 2025-01-24
TWI902665B (zh) 2025-11-01
MA53099A (fr) 2021-05-12
AU2019299352B2 (en) 2025-02-27
UA129800C2 (uk) 2025-08-06
AU2025203835A1 (en) 2025-06-12
US20210323944A1 (en) 2021-10-21
IL327008A (en) 2026-05-01
IL279877A (en) 2021-03-01
EP4603147A3 (en) 2025-10-01
BR112021000156A2 (pt) 2021-04-06
KR20210029775A (ko) 2021-03-16
MX2023011687A (es) 2023-10-19
PH12021550017A1 (en) 2021-09-13
KR20250164882A (ko) 2025-11-25
JP2024150784A (ja) 2024-10-23
EP3817744A1 (en) 2021-05-12
AU2019299352A1 (en) 2021-01-07
WO2020010058A1 (en) 2020-01-09
US12264148B2 (en) 2025-04-01
SG11202012763TA (en) 2021-02-25
IL315423A (en) 2024-11-01
ZA202008034B (en) 2021-10-27
EP4603147A2 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
AU2019246824B2 (en) Pharmaceutical compositions of therapeutically active compounds and their methods of use
AU2019232825B2 (en) Pharmaceutical compositions of therapeutically active compounds
JP2024150784A (ja) イボシデニブ形態および医薬組成物
HK40129554A (en) Ivosidenib forms and pharmaceutical compositions
EA048347B1 (ru) Формы ивосидениба и фармацевтические композиции
EA053032B1 (ru) Формы ивосидениба и фармацевтические композиции
HK40044696A (en) Pharmaceutical compositions of therapeutically active compounds and uses thereof
HK40043528A (en) Pharmaceutical compositions of therapeutically active compounds
HK1233185B (en) Pharmaceutical compositions of therapeutically active compounds
BR122023021440B1 (pt) Composições farmacêuticas para tratar câncer
EA051161B1 (ru) Фармацевтические композиции терапевтически активных соединений

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220921

Address after: Syrene, France

Applicant after: LES LABORATOIRES SERVIER

Address before: Massachusetts

Applicant before: AGIOS PHARMACEUTICALS, Inc.

TA01 Transfer of patent application right